Compare Inovio Pharmaceuticals Inc (INO) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Oklo Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Oklo Inc trades at $43.52 (market cap $7.22B). The key difference: Oklo Inc is far larger — about 80.9× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| INO | OKLO | |
|---|---|---|
Market Cap | $89.27M | $7.22B |
Sector | Health | Technology |
52-Week High | $2.87 | $174.14 |
52-Week Low | $1.05 | $41.11 |
Enterprise Value | $60.28M | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
OKLO trades at $41.51, down 42% year-to-date amid regulatory uncertainty and recent stock dilution. The company shows strong analyst support with 77% buy ratings and a $90.88 consensus price target, but fundamentals remain weak with negative earnings and cash flow. Recent news highlights progress on nuclear projects but regulatory hurdles persist.
OKLO presents high-risk/high-reward potential with significant upside to analyst targets but faces execution risks and negative profitability. The stock's bearish technical signals contrast with bullish long-term nuclear energy thesis. Regulatory approvals and Meta partnership execution remain critical catalysts for valuation recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
